Trevi Therapeutics Plans Conference Call and Webcast to Announce Phase 2a RIVER Trial Results for Haduvio

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for March 10th. This event will discuss the topline results from the Phase 2a RIVER trial of Haduvio™ (nalbuphine ER) in patients with refractory chronic cough.

Details of the Scheduled Event

The conference call and webcast are set for Tuesday, March 10, 2023, at 8:00 AM Eastern Time. Interested parties can access the live webcast through the Investors section of Trevi’s website. Additionally, a replay of the webcast will be available on the website shortly after the conclusion of the call.

Focus of the RIVER Trial

Haduvio™, which is being investigated by Trevi Therapeutics, targets patients suffering from refractory chronic cough. This condition is characterized by a cough persisting for more than eight weeks, despite the use of current medications. The RIVER trial is crucial as it evaluates the efficacy and safety of Haduvio™ in providing relief from this condition.

Trevi Therapeutics has emphasized the significance of this trial in a statement released ahead of the event. “We are eager to share the findings from the Phase 2a RIVER trial, which explored Haduvio’s potential as a treatment for refractory chronic cough,” explained the CEO, who will also be addressing participants during the call.

Corporate Background

Based in New Haven, Connecticut, Trevi Therapeutics is dedicated to the advancement of nalbuphine ER (extended-release) for multiple indications. The company’s focus lies in addressing significant unmet medical needs, particularly in the fields of chronic cough and pruritus (severe itching).

For further information and updates, you can follow Trevi Therapeutics through their press releases and website updates.

Note: Investors and stakeholders are encouraged to access the conference call via the designated link or dial into the conference call using the details provided on Trevi’s official website.